Phase II Study of Denosumab (NSC# 744010) a RANK Ligand Antibody for Recurrent or Refractory Osteosarcoma
Brief description of study
This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Monoclonal antibodies, such as denosumab, may block tumor growth in different ways by targeting certain cells.
Clinical Study Identifier: s15-01360
ClinicalTrials.gov Identifier: NCTs15-01360
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
